Information Provided By: 
Fly News Breaks for August 10, 2017
PBYI
Aug 10, 2017 | 07:57 EDT
JPMorgan analyst Cory Kasimov raised his price target for Puma Biotechnology to $105 following the Q2 earnings report. The earnings contained nothing new ahead of the full launch of Nerlynx expected this September, Kasimov tells investors in a research note. The analyst continues to view Puma's "scarcity value" as attractive. He keeps an Overweight rating on the name.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
